Liraglutide add-on to insulin degludec plus metformin vs addition of a single dose of insulin aspart to the largest meal in patients with Type 2 diabetes

被引：0
|
作者：
Russell-Jones, D. [1 ,2 ]
Mathieu, C. [3 ]
Rodbard, H. W. [4 ]
Cariou, B. [5 ]
Handelsman, Y. [6 ]
Philis-Tsimikas, A. [7 ]
Francisco, A. M. Ocampo [8 ]
Rana, A. [8 ]
Zinman, B. [9 ]
机构：
[1] Royal Surrey Cty Hosp, Guildford, Surrey, England
[2] Univ Surrey, Guildford GU2 5XH, Surrey, England
[3] Katholieke Univ Leuven, UZ Gasthuisberg, Louvain, Belgium
[4] Endocrine & Metab Consultants, Rockville, MD USA
[5] CHU Nantes, Inst Thorax, Clin Endocrinol, F-44035 Nantes 01, France
[6] Metab Inst Amer, Tarzana, CA USA
[7] Scripps Hlth, Scripps Whittier Diabet Inst, La Jolla, CA USA
[8] Novo Nordisk AS, Soborg, Denmark
[9] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada
来源：
DIABETIC MEDICINE | 2014年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [31] Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes
    Kvapil, A
    Swatko, A
    Hilberg, C
    Shestakova, A
    DIABETES OBESITY & METABOLISM, 2006, 8 (01): : 39 - 48
  • [32] Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea
    P. Khaloo
    S. Asadi Komeleh
    H. Alemi
    M. A. Mansournia
    A. Mohammadi
    A. Yadegar
    M. Afarideh
    S. Esteghamati
    M. Nakhjavani
    A. Esteghamati
    Journal of Endocrinological Investigation, 2019, 42 : 851 - 857
  • [33] Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea
    Khaloo, P.
    Komeleh, S. Asadi
    Alemi, H.
    Mansournia, M. A.
    Mohammadi, A.
    Yadegar, A.
    Afarideh, M.
    Esteghamati, S.
    Nakhjavani, M.
    Esteghamati, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (07) : 851 - 857
  • [34] Patient-reported outcomes for insulin degludec/liraglutide vs insulin glargine as add-on to sodium-glucose co-transporter-2 inhibitor in type 2 diabetes: DUAL IX trial
    Brod, M.
    Billings, L.
    Busch, R.
    Harris, S.
    Morales Portillo, C.
    Sahay, R.
    Busk, A.
    Eggert, S.
    Halladin, N.
    Philis-Tsimikas, A.
    DIABETOLOGIA, 2018, 61 : S412 - S413
  • [35] Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus
    Staels, Frederik
    Moyson, Carolien
    Mathieu, Chantal
    DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1463 - 1467
  • [36] Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes
    Ma, J.
    Yang, W.
    Hong, T.
    Liu, M.
    Miao, H.
    Peng, Y.
    Wang, C.
    Xu, X.
    Yang, T.
    Liu, W.
    Nielsen, A. Moeller
    Pan, L.
    Weigang, Z.
    DIABETOLOGIA, 2018, 61 : S410 - S411
  • [37] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Liu, C.
    Tao, L. B.
    Wang, F.
    VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [38] Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
    Heo, Young-A
    DRUGS & THERAPY PERSPECTIVES, 2020, 36 (06) : 219 - 229
  • [39] Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
    Young-A Heo
    Drugs & Therapy Perspectives, 2020, 36 : 219 - 229
  • [40] Fixed Combination of Insulin Degludec and Liraglutide in Type 2 Diabetes Treatment
    Jaecke, E.
    Wilhelm, B.
    Kaiser, M.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (06): : 387 - 395
12345